Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
shop dildos - is great for every girl.
Popular Articles

Additional Phase II Data Demonstrate Improvement In Reported Symptoms In Patients Who Still Experience GERD Symptoms Despite PPI Therapy
Adding AZD3355, a novel GABAB receptor agonist, to a proton pump inhibitor (PPI) in patients with Gastroesophageal Reflux Disease (GERD), resulted in a 35% reduction in the mean total number of reflux episodes 0-24 hours after dose, compared with placebo.[i] These data were presented at the Digestive Diseases Week annual meeting (DDW®, 30 May - 4 June, Chicago).
drugs without prescription
Method To Efficiently Produce Less Toxic Drugs Using Organic Molecules Discovered By NTU Professor
Nanyang Technological University (NTU)"s Associate Professor Zhong Guofu has made a significant contribution to the field of organic chemistry, in particular the study of using small organic molecules as catalysts, in the synthesis process called organocatalysis. Such synthesis process takes place for example, during the production of chiral drugs.
News of the day
Gene Transfer Technology May Lead To HIV Vaccine
A research team may have broken the impasse that has frustrated HIV vaccine researchers by using an unconventional approach that bypasses the usual vaccine development path. Using gene transfer technology to produces molecules that block infection, the scientists protected monkeys from infection by a virus closely related to HIV -- the simian immunodeficiency virus, or SIV. "We used a leapfrog strategy, bypassing the natural immune system response that was the target of previous HIV and SIV vaccine candidates," explains study leader Philip R. Johnson, MD, chief scientific officer at The Children"s Hospital of Philadelphia and professor of pediatrics at the University of Pennsylvania. Johnson and colleagues reported their work in Nature Medicine Most attempts at developing an HIV vaccine have used substances aimed at stimulating the body"s immune system to produce antibodies that would eliminate the virus before or after it infected cells. In clinical trials, however, these vaccines have not elicited protective immune responses, just as the body fails on its own to produce an effective response during natural HIV infection.
Health Insurance

IKARIA(R) To In-License BioLineRx's BL-1040

Ikaria Holdings, Inc. and BioLineRx Ltd. (TASE: BLRX) announced that Ikaria has entered into an agreement to obtain a worldwide exclusive license to BioLineRx"s BL-1040, a potential breakthrough treatment for preventing pathological cardiac remodeling following acute myocardial infarction (AMI). BL-1040, currently in a phase I/II clinical trial, is administered via the coronary artery during standard catheterization and flows into the damaged heart muscle, where it forms a protective "scaffold" that enhances the mechanical strength of the heart muscle during recovery and repair. BL-1040 is the first program to graduate from the BIJ (BioLine Innovations Jerusalem) incubator subsidized by the Israeli Office of the Chief Scientist. Under the terms of the agreement, BioLineRx will receive upfront and milestone payments. BioLineRx will also receive royalties on annual net sales. Ikaria will be responsible for completing clinical development and commercialization efforts. The deal is contingent upon receipt of the approval of the Israeli Office of the Chief Scientist. "The acquisition of the rights to BL-1040 reinforces our commitment to deliver novel treatments to critically ill patients around the world," commented Daniel Tasse, President and CEO of Ikaria. "Millions of patients suffer from MI each year, and BL-1040 represents the potential of an exciting solution to the problem of ventricular remodeling following AMI, for which the unmet need remains very high." "This agreement is consistent with our business model of developing early-stage programs through human Proof of Concept trials and ultimately partnering with a global therapeutics company that has the expertise and res to complete development and commercialization," said Morris C. Laster, M.D., CEO of BioLineRx. "Ikaria"s deep and singular focus on therapies for patients in acute care settings makes it an ideal party to further develop and bring BL-1040 to the global market." About BL-1040 BL-1040 was invented by Professor Smadar Cohen from Ben-Gurion University and Professor Jonathan Leor from Tel-Aviv University. BioLineRx in-licensed the technology in 2005 from Ben-Gurion University through B.G. Negev Technologies and Applications Ltd. BL-1040 is currently in a Phase I/II pilot study in Germany and Belgium to determine the safety and feasibility of BL-1040 to treat AMI. Final results are anticipated in Q4 2009. About Ikaria Holdings, Inc. Ikaria Holdings, Inc. is a biotherapeutics company whose acute care products and therapies address the significant unmet needs of critically ill patients. The company"s lead product, INOmax(R) (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Latin America and Australia. INOmax is approved for marketing in Japan and Mexico. Ikaria is engaged in new and ongoing clinical development of INOmax, carbon monoxide for inhalation and hydrogen sulfide. Ikaria also acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. Ikaria Holdings, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009